Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neuroendocrine Tumors 14 Carcinoid Tumor 5 Gastro-enteropancreatic neuroendocrine tumor 4 Acromegaly 4 Serotonin Syndrome 2 Pituitary Neoplasms 2 Neoplasm Metastasis 2 Carcinoma, Hepatocellular 2 Prostatic Neoplasms 1 Pheochromocytoma 1 Peritoneal Neoplasms 1 Paraganglioma 1 Pancreatic Neoplasms 1 Neuroendocrine Tumour With Carcinoid Symptoms 1 Neuroendocrine Tumors in Lung 1 Neoplastic Cells, Circulating 1 Neoplasms 1 Intestinal Obstruction 1 Growth Hormone-Secreting Pituitary Adenoma 1 Gigantism 1 Gastrointestinal Neoplasms 1 Flushing 1 Endocrine Tumors 1 Diarrhea 1 Carcinoma, Merkel Cell 1 Carcinoma 1 Carcinoid Heart Disease 1 Adenoma, Islet Cell 1

Interventions

pembrolizumab 29 avelumab 21 Nivolumab 20 Ipilimumab 10 Radiotherapy 9 Cyclophosphamide 9 atezolizumab 8 cemiplimab 7 fludarabine 6 Specimen Handling 6 durvalumab 5 aldesleukin 5 Radiation 5 Magnetic Resonance Spectroscopy 5 Interleukin-2 5 Biopsy 5 talimogene laherparepvec 4 ALT-803 4 poly ICLC 3 Radiosurgery 3 Etoposide 3 Cisplatin 3 Carboplatin 3 CTLA-4 Antigen 3 Bevacizumab 3 prednylidene 2 lutetium Lu 177 dotatate 2 fludarabine phosphate 2 domatinostat 2 deltacortene 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Merkel Cell × lanreotide × Clear all

NCT02351128 2017-10-18

PHRC-Merkel

University Hospital, Grenoble

Phase 2 Completed

Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡